Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Rating Lowered by TheStreet

Posted on July 31, 2017 by

Several other equities analysts also recently weighed in on VRTX. UBS AG reaffirmed a “buy” rating and issued a $135.00 price objective on shares of […]

Read the original post by AmericanBankingNews.com